Health software startup Osmind has announced the hiring of leading neuroscience researcher Dr. Robin Carhart-Harris as a Scientific Advisor. Dr. Carhart-Harris’ role will be to advise the company on strategies to support the discovery, development, commercialization, and delivery of novel mental health therapies, particularly the efficacy of psychedelics.
“We are thrilled to welcome Dr. Carhart-Harris to our Scientific Advisory Board,” said Osmind Medical Director L. Alison McInnes. “His expertise across psychedelic modalities will be invaluable for us to deepen our software’s utility and ability to aggregate useful insights for researchers, clinicians and patients. Collectively, our team has expertise across technology, psychiatry, neuroscience, and more to advance therapeutics for treatment resistant mental health conditions.”
Dr. Carhart-Harris is head of the Centre for Psychedelic Research at Imperial College London, where he has led a range of studies and trials involving psilocybin, LSD, MDMA, and DMT. He has published more than 100 papers in peer-reviewed scientific journals and is a thought leader in the encouraging field of psychedelic-based therapies for mental health patients for whom antidepressants are ineffective.
“I have been impressed with Osmind’s progress in the ketamine therapy space, filling an important need with regard to digital health recording and data capture,” said Dr. Carhart-Harris. “I am delighted to have this opportunity to contribute to their continued success.”